Gap Analysis

Our services along the whole product lifecycle

Services by stage

Discover all our Drug Development services

Drug Development Regulatory Affairs Market Access Pharmacovigilance Quality & Compliance Case Studies

Drug Development

Drug Development Strategy Gap Analysis SME Status Orphan Drug Designation (ODD) Scientific Advice Pediatric Investigation Plan (PIP) PRIME (PRIority MEdicines) scheme CMC Regulatory solutions Clinical Trial Application (CTA) Due Diligence

Regulatory Affairs

Registration Strategy Marketing Authorization Application (MAA) CMC Regulatory solutions Dossier Development Life cycle management Due Diligence Launch readiness Advertising & Promotion

Market Access

Early Access Programs Market Access Strategy Pricing & Reimbursement Dossier Health Economic Models Negotiation with Health Authorities Pricing & Reimbursement maintenance Joint Clinical Assessment (JCA) Integrated strategy and execution in the European markets

Pharmacovigilance

QPPV Services EudraVigilance services Pharmacovigilance System Master File (PSMF) Local Pharmacovigilance

Quality & Compliance

A KEY MILESTONE

Complementary to the Drug Development strategy is the gap analysis. The goal is to identify any missing aspects in the company’s data package to avoid missteps that may render the data inconclusive or require additional time, effort, and costs. This is key to revealing risks to the success of an asset or development program and to optimize resources and ensure funding through completion.
Findings are used to develop informed strategies and to identify the best and most appropriate regulatory and market access approach.

Pharmaceutical & BioTech